Advertisement|Remove ads.

Shares of Senseonics Holdings (SENS) plunged roughly 18% premarket on Friday after the medical device company priced an $80 million equity offering at $5 per share—a capital raise that immediately capped the stock near the offering price and triggered a wave of sell-off.
Senseonics closed Thursday’s session at $6.61 per share, then announced a $5.00 stock offering after the bell—sending the stock tumbling in premarket trading.
This discounted pricing adds to dilution concerns and acts as a near-term ceiling, as new shares enter the market at a lower benchmark.
On Stocktwits, one user expressed displeasure with the stock's pricing and questioned why anyone would pay more for the stock when the company itself had just sold shares at $5.
While another user said, the shareholders are experiencing a ‘classic biotech paradox’
On Thursday, Senseonics priced 8 million shares at $5.00 and 8 million pre-funded warrants at $4.999, with each warrant exercisable for a share at $0.001.
In addition, Senseonics gave the underwriters a 30-day option to buy up to 2.4 million more shares at the same $5 offering price, minus their fees.
The company said the offering would close on May 4, 2026.
The company also said the gross proceeds from the offering would be at $80 million.
Sensionics also stated that it intends to use net proceeds to fund the ongoing launch of Eversense 365, development of its other products, and working capital, among others.
On Stocktwits, retail sentiment surrounding the stock has improved to ‘bullish’ from ‘bearish’ while message volumes rose to ‘extremely high.’

Shares of Sensionics Holdings have risen more than 12% year-to-date.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Read Next: RBLX Stock Crashes 24% Pre-Market: Analysts Warn Of ‘Credibility Reset’